Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.76)
# 3,357
Out of 5,143 analysts
60
Total ratings
44.19%
Success rate
-1.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $24 → $33 | $28.51 | +15.75% | 7 | Dec 15, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $141 → $157 | $98.54 | +59.33% | 11 | Dec 12, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Neutral | $27 → $30 | $32.21 | -6.86% | 6 | Oct 21, 2025 | |
| GERN Geron | Reinstates: Sell | $1 | $1.60 | -37.30% | 4 | Jul 10, 2025 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $30.13 | -26.98% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $9.25 | +62.16% | 2 | May 14, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $4.55 | +186.03% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $28.71 | -2.47% | 7 | Jan 9, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $1.65 | +3,778.79% | 6 | Aug 15, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $216 → $184 | $57.95 | +217.52% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $3.30 | +537.33% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $41.26 | -66.07% | 2 | Dec 20, 2022 |
Roivant Sciences
Dec 15, 2025
Maintains: Buy
Price Target: $24 → $33
Current: $28.51
Upside: +15.75%
Rhythm Pharmaceuticals
Dec 12, 2025
Maintains: Buy
Price Target: $141 → $157
Current: $98.54
Upside: +59.33%
IDEAYA Biosciences
Oct 21, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $32.21
Upside: -6.86%
Geron
Jul 10, 2025
Reinstates: Sell
Price Target: $1
Current: $1.60
Upside: -37.30%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $30.13
Upside: -26.98%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $9.25
Upside: +62.16%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $4.55
Upside: +186.03%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $28.71
Upside: -2.47%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $1.65
Upside: +3,778.79%
RAPT Therapeutics
Mar 15, 2023
Maintains: Buy
Price Target: $216 → $184
Current: $57.95
Upside: +217.52%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $3.30
Upside: +537.33%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $41.26
Upside: -66.07%